product name Trelagliptin
Description: Trelagliptin, also known as SYR-472, is a highly selective, long-acting DPP-4 inhibitor. Once-weekly Trelagliptin treatment produced clinically and statistically significant improvements in glycaemic control in patients with type 2 diabetes. It was well tolerated and might be a new treatment option for patients with this disease. Trelagliptin was approved in Japan for the treatment of type 2 diabetes mellitus (T2DM).
References: Lancet Diabetes Endocrinol. 2014 Feb;2(2):125-32.
357.38
Formula
C18H20FN5O2
CAS No.
865759-25-7
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 71 mg/mL (198.7 mM)
Water: <1 mg/mL
Ethanol: 3 mg/mL warmed (8.4 mM)
Solubility (In vivo)
Synonyms
SYR-472
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19414931
| In Vitro |
In vitro activity: Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Trelagliptin improves glycaemic control by inhibition of DPP-4 activity. |
| Animal model | |
| Formulation & Dosage | |
| References | Lancet Diabetes Endocrinol. 2014 Feb;2(2):125-32. |
